EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and
emerging infectious diseases and pandemics. The purpose of this study is to evaluate the
effect of a range of interventions to improve outcome of patients admitted to hospital with
COVID-19. The platform is designed for running phase 2 and phase 3 trials, and with modular
data capture (end point/safety data, biobanking, add-on studies) depending on the capacity of
participating sites. The study consists of two parts with different primary end points
depending on disease stage: EU SolidAct part A includes hospitalized patients with moderate
disease, whereas EU SolidAct part B includes hospitalized patients with severe and critical
disease.